https://orcid.org/0000-0002-6099-9894
References
- Busari AA, Oreagba IA, Oshikoya KA, Kayode MO, Olayemi SO. High risk of drug-drug interactions among hospitalized patients with kidney diseases at a Nigerian Teaching Hospital: a call for action. Niger Med J. 2019;60(6):317–325. doi:10.4103/nmj.NMJ_2_1932180663
- Pirmohamed M. Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wien Klin Wochenschr. 2010;122(3–4):62–64. doi:10.1007/s00508-010-1309-120213370
- Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–675. doi:10.2165/11534400-000000000-0000020635825
- Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–497. doi:10.1002/pds.359224616171
- Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–558. doi:10.1038/nrc188716794637
- Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006;24(7):704–712. doi:10.1080/0735790060106376617118781
- Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–4150. doi:10.1200/JCO.2015.65.394926926685
- Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166–3174. doi:10.1200/JCO.2016.67.634627458288
- Lapalombella R, Sun QX, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621–4634. doi:10.1182/blood-2012-05-42950623034282
- Yoshimura M, Ishizawa J, Ruvolo V, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105(7):795–801. doi:10.1111/cas.1243024766216
- FDA grants accelerated approval to selinexor for multiple myeloma. Case Med Res. 2019.
- Chen C, Kotb R, Sebag M, et al. Selinexor shows synergy in combination with pomalidomide and low dose dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2016;128(22). doi:10.1182/blood-2016-06-724161
- Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554. doi:10.1182/blood-2018-06-85885230352784
- ClinicalTrials.gov. Selinexor and backbone treatments of multiple myeloma patients (STOMP). Accessed 67, 2019.
- Karyopharm Therapeutics Inc. XPOVIO™ (selinexor) tablets, for oral use: US prescribing information. 2019 Accessed 82, 2019.
- Syed YY. Selinexor: first global approval. Drugs. 2019;79(13):1485–1494. doi:10.1007/s40265-019-01188-931429063
- US Food and Drug Administration. Guidance for Indus-Try: Bioanalytical Method Validation. Rockville, MD, USA: US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research; 2018 Accessed 810, 2018.
- Toivo TM, Mikkola JA, Laine K, Airaksinen M. Identifying high risk medications causing potential drug-drug interactions in outpatients: a prescription database study based on an online surveillance system. Res Social Adm Pharm. 2016;12(4):559–568. doi:10.1016/j.sapharm.2015.09.00426459026
- Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907–1912. doi:10.1093/annonc/mdp36919713244